---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-128299"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:04:56.214361+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma appoints Irenic's Jeremy Grant to board, enters cooperation agreement, reaffirms capital return

## Summary
- Jeremy Grant appointed to Board as Class II director; Board temporarily expands to 10.
- Cooperation agreement with Irenic includes standstill, voting commitments, and information sharing rights.
- Company reaffirms commitment to return all excess capital; $300M returned since mid-2022, shares reduced ~35%.
- Dr. Burton Malkiel not standing for re-election at May 2024 AGSM; Board will revert to 9 directors.

## SEC filing metadata
- accession: 0001104659-23-128299
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/0001104659-23-128299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/tm2333517d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-128299
- JSON: https://secwatch.observer/filing/0001104659-23-128299.json
- Plain text: https://secwatch.observer/filing/0001104659-23-128299.txt

## Key facts
- Executive change
  Jeremy Grant was appointed as Director at Theravance Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: In connection with the Cooperation Agreement, the New Director was appointed to the Board, as well as the Development and Commercialization Committee and the Compensation Committee, each effective December 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/0001104659-23-128299-index.htm
- Material Agreements
  Theravance Biopharma, Inc. entered into Cooperation Agreement with Irenic Capital Management LP, Irenic Capital Management GP LLC, Irenic Capital Evergreen Master Fund LP, Irenic Capital Evergreen Fund GP LLC (effective 2023-12-21).
  - Action: entry
  - Counterparty: Irenic Capital Management LP, Irenic Capital Management GP LLC, Irenic Capital Evergreen Master Fund LP, Irenic Capital Evergreen Fund GP LLC
  - Effective: 2023-12-21
  source text: On December 21, 2023, Theravance Biopharma, Inc., a Cayman Islands exempted company (the “Company”), entered into a cooperation agreement (the “Cooperation Agreement”) with Irenic Capital Management LP, a Delaware limited partnership, Irenic Capital Management GP LLC, a Delaware limited liability company, Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership, and Irenic Capital Evergreen Fund GP LLC, a Delaware limited liability company (collectively “Irenic”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/0001104659-23-128299-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.